お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
1006259

皮膚癌診断および治療薬市場調査レポート:疾患タイプ別、診断別、治療別-2026年までの予測-COVID-19の累積的影響

Skin Cancer Diagnostics & Therapeutics Market Research Report by Disease Type, by Diagnosis, by Treatment, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.33円
皮膚癌診断および治療薬市場調査レポート:疾患タイプ別、診断別、治療別-2026年までの予測-COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の皮膚癌診断および治療薬の市場規模は、2020年の56億5,687万米ドルから、2025年末までに88億4,705万米ドルに拡大すると予測されています。

COVID-19は、未曾有の世界的な公衆衛生上の緊急事態であり、あらゆる業界に影響を及ぼしてきました。この長期的影響は、予測期間中に業界の成長に影響を与えると予測されています。私たちが進めている調査では、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げています。当レポートは、消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19について洞察を提供しています。アップデートされた調査では、COVID-19が市場に及ぼす影響を考慮し、洞察、分析、予測などを提供しています。

当レポートでは、皮膚癌診断および治療薬市場について調査し、市場の概要とともに、疾患タイプ別、診断別、治療別、地域別の動向、COVID-19の累積的影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションと範囲
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画作成
    • 実行:調査実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • 疾患タイプ別見通し
  • 診断別見通し
  • 治療別見通し
  • 地域別見通し
  • 競合他社別見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 皮膚癌診断および治療薬市場、疾患タイプ別

  • 黒色腫
  • 非黒色腫

第7章 皮膚癌診断および治療薬市場、診断別

  • 血液検査
  • ダーモスコピー
  • 画像検査
  • リンパ節生検
  • 皮膚生検

第8章 皮膚癌診断および治療薬市場、治療別

  • 化学療法
  • 非侵襲的療法
  • 手術

第9章 南北アメリカの皮膚癌診断および治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の皮膚癌診断および治療薬市場

  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第11章 欧州、中東・アフリカの皮膚癌診断および治療薬市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 契約、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第13章 企業のユーザビリティプロファイル

  • AB Science
  • Abbott Laboratories
  • Amgen, Inc
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Castle Biosciences, Inc
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • NeraCare GmbH
  • Novartis AG
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格
  • 連絡先の詳細
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2026
  • FIGURE 11. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2020 VS 2026 (%)
  • FIGURE 16. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2026
  • FIGURE 18. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, 2018-2026 (USD MILLION)
  • FIGURE 19. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, 2018-2026 (USD MILLION)
  • FIGURE 21. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, 2018-2026 (USD MILLION)
  • FIGURE 23. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, 2018-2026 (USD MILLION)
  • FIGURE 25. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 26. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, 2018-2026 (USD MILLION)
  • FIGURE 27. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 28. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2020 VS 2026 (%)
  • FIGURE 29. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2020 VS 2026 (USD MILLION)
  • FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2026
  • FIGURE 31. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2026 (USD MILLION)
  • FIGURE 36. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 38. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 40. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. CALIFORNIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. FLORIDA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. ILLINOIS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. NEW YORK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. OHIO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. PENNSYLVANIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. TEXAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 53. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 54. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 55. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 56. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 57. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 64. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 65. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 66. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 76. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 77. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 78. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 79. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 80. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. CALIFORNIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. CALIFORNIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. CALIFORNIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. FLORIDA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. FLORIDA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. FLORIDA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. ILLINOIS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. ILLINOIS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. ILLINOIS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. NEW YORK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. NEW YORK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. NEW YORK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. OHIO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. OHIO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. OHIO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. PENNSYLVANIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. PENNSYLVANIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. PENNSYLVANIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. TEXAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. TEXAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. TEXAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. RUSSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. SAUDI ARABIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. SOUTH AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. SPAIN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. UNITED ARAB EMIRATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 119. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 120. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 121. UNITED KINGDOM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 122. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SCORES
  • TABLE 123. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 124. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 125. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: RANKING
  • TABLE 126. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 127. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 128. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 129. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 130. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 131. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 132. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 133. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: LICENSE & PRICING
  • TABLE 134. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET: CONTACT DETAILS
目次
Product Code: MRR-4342CA3266EE

The Global Skin Cancer Diagnostics & Therapeutics Market size was estimated at USD 5,656.87 Million in 2020 and expected to reach USD 6,214.44 Million in 2021, at a Compound Annual Growth Rate (CAGR) 10.19% to reach USD 10,128.49 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Skin Cancer Diagnostics & Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease Type, the Skin Cancer Diagnostics & Therapeutics Market was studied across Melanoma and Non-melanoma.

Based on Diagnosis, the Skin Cancer Diagnostics & Therapeutics Market was studied across Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy.

Based on Treatment, the Skin Cancer Diagnostics & Therapeutics Market was studied across Chemotherapy, Non-invasive Therapy, and Surgery.

Based on Geography, the Skin Cancer Diagnostics & Therapeutics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Skin Cancer Diagnostics & Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Skin Cancer Diagnostics & Therapeutics Market, including AB Science, Abbott Laboratories, Amgen, Inc, Amgen, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Castle Biosciences, Inc, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Merck & Co., Inc., NeraCare GmbH, Novartis AG, Pfizer Inc., Qiagen NV, Sanofi SA, and Sun Pharmaceutical Industries Ltd..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Skin Cancer Diagnostics & Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 6. What is the market share of the leading vendors in the Global Skin Cancer Diagnostics & Therapeutics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Skin Cancer Diagnostics & Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Disease Type Outlook
  • 3.4. Diagnosis Outlook
  • 3.5. Treatment Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of skin cancer globally
      • 5.1.1.2. Rising awareness on skin cancer among people
      • 5.1.1.3. Proliferation in research and development pipelines for skin cancer drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging advanced healthcare infrastructure globally
      • 5.1.3.2. Introduction of new diagnostics and therapeutic products
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulatory mandates for diagnostics and therapeutics
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Skin Cancer Diagnostics & Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Melanoma
  • 6.3. Non-melanoma

7. Skin Cancer Diagnostics & Therapeutics Market, by Diagnosis

  • 7.1. Introduction
  • 7.2. Blood Tests
  • 7.3. Dermatoscopy
  • 7.4. Imaging Tests
  • 7.5. Lymph Node Biopsy
  • 7.6. Skin Biopsy

8. Skin Cancer Diagnostics & Therapeutics Market, by Treatment

  • 8.1. Introduction
  • 8.2. Chemotherapy
  • 8.3. Non-invasive Therapy
  • 8.4. Surgery

9. Americas Skin Cancer Diagnostics & Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Skin Cancer Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Skin Cancer Diagnostics & Therapeutics Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. AB Science
  • 13.2. Abbott Laboratories
  • 13.3. Amgen, Inc
  • 13.4. Amgen, Inc.
  • 13.5. AstraZeneca PLC
  • 13.6. Bristol-Myers Squibb Company
  • 13.7. Castle Biosciences, Inc
  • 13.8. Daiichi Sankyo Company, Limited
  • 13.9. F. Hoffmann-La Roche Ltd
  • 13.10. GlaxoSmithKline PLC
  • 13.11. Merck & Co., Inc.
  • 13.12. NeraCare GmbH
  • 13.13. Novartis AG
  • 13.14. Pfizer Inc.
  • 13.15. Qiagen NV
  • 13.16. Sanofi SA
  • 13.17. Sun Pharmaceutical Industries Ltd.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.